Par Pharmaceutical, QOL Medical deal

Par's Strativa Pharmaceuticals division acquired exclusive, worldwide rights to QOL's Nascobal cyanocobalamin nasal spray for $54.5 million in cash. The once-weekly spray is marketed in the U.S. to m...